Chong Kun Dang said it has won the lawsuit against Novartis over the patent of Novartis’ immunosuppressant Certican (ingredient: everolimus).
|Chong Kun Dang’s immunosuppressant Certirobel|
The Supreme Court struck down Novartis’ appeal on Aug. 30, which claimed that Chong Kun Dang’s Certirobel, a generic drug of Certican, infringed upon Certican’s patent.
In July 2017, Chong Kun Dang sought a lawsuit against Novartis to recognize its passive scope of rights over the patent of “stabilization of macrolides” in Certican, and the court ruled in favor of Chong Kun Dang. Novartis appealed, but the court rejected the appeal in February. Novartis did not accept it and appealed again. The Supreme Court dismissed the appeal finally.
Chong Kun Dang obtained sales license of Certirobel in November and released it with insurance benefit in January. The drugmaker secured exclusive rights to sell the first generic drug of Certican by October this year.
Novartis’ Certican sold 5.5 billion won ($4.6 million) last year, according to IQVIA data.
<© Korea Biomedical Review, All rights reserved.>